Drug Trial Radar · NCT06530966
Phase I Study of ICP-332 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Apr 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 23, 2024
Primary completion
Nov 8, 2024
Study completion Nov 8, 2024
Sponsor
- Lead sponsor
- InnoCare Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A multiple ascending dose phase I study of ICP-332 in healthy subjects
Conditions
- Healthy Subjects
Interventions
ICP-332 TabletsDrug
Eligible patients will receive ICP-332 tablets orally as per the protocol
ICP-332 Placebo TabletsDrug
Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs)Time frame: Up to Day 28
- Number of Participants With Clinically Significant Change in Vital SignsTime frame: Up to Day 28
- Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)Time frame: Up to Day 28
- Number of Participants With Clinically Significant Change in Physical ExaminationTime frame: Up to Day 28
- Number of Participants With Clinically Significant Change in Clinical Laboratory ValuesTime frame: Up to Day 28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Pharmaron CPC Inc.
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.